Document Detail

Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
MedLine Citation:
PMID:  20107305     Owner:  NLM     Status:  MEDLINE    
Prasugrel was associated with a statistically significant reduction in rates of cardiac ischemic events in patients with ACS who had undergone PCI. Rates of post-PCI death from cardiovascular causes, nonfatal MI, or nonfatal stroke were also significantly reduced with the use of prasugrel versus clopidogrel. Major bleeding was significantly increased with the use of prasugrel versus clopidogrel. Mortality did not differ significantly between the groups.
Scott Solomon; James L Vacek
Related Documents :
18388505 - Major clinical vascular events and aspirin-resistance status as determined by the pfa-1...
2382605 - Unstable angina or non-q wave infarction despite long-term aspirin: response to thrombo...
18081375 - Parnaparin : a review of its use in the management of venous thromboembolism, chronic v...
9727545 - Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a d...
10335875 - Plasma lipids, lipoproteins and apolipoproteins and sudden cardiac death.
19131865 - Near infrared spectroscopy changes with pericardial tamponade.
Publication Detail:
Type:  Clinical Trial, Phase III; Comment; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Postgraduate medicine     Volume:  122     ISSN:  1941-9260     ISO Abbreviation:  Postgrad Med     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-01-28     Completed Date:  2010-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401147     Medline TA:  Postgrad Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  198-200     Citation Subset:  AIM; IM    
The University of Kansas Medical Center and Hospital, 39th and Rainbow Blvd., Kansas City, KS 66106, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / complications*,  drug therapy
Aspirin / therapeutic use
Confidence Intervals
Double-Blind Method
Drug Therapy, Combination
Myocardial Ischemia / drug therapy,  etiology,  prevention & control*
Piperazines / therapeutic use*
Platelet Aggregation Inhibitors / therapeutic use
Pyridines / therapeutic use
Thiophenes / therapeutic use*
Ticlopidine / analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Pyridines; 0/Thiophenes; 0/prasugrel; 0/thienopyridine; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel
Comment On:
N Engl J Med. 2007 Nov 15;357(20):2001-15   [PMID:  17982182 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary.
Next Document:  Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Comm...